Answers are grounded in this paper and cite their sources.
The higher levels of receptor occupancy necessary for DORA efficacy require a plasma concentration profile sufficient to maintain sleep for the duration of the resting period. DORAs, with a half-life exceeding 8 h in humans, are expected to fulfill this requirement as exposures drop to sub-threshold receptor occupancy levels prior to the wake period, potentially avoiding next-day residual effects at therapeutic doses.
No takes yet. Share an insight, caveat, or question.
Gotter et al. (2013) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: